Test
Used for the optimization of transfection and verification of editing efficiency in transfected cells.
Ambion™ Carrier RNA (1 mg/mL) is a component of all the MagMAX™ Isolation Kits that may be purchased separately.
Non-targeting gRNA sequences that do not recognize any sequence in the human or mouse genome.
Superior quality GeneArt CRISPR Nuclease mRNA is formulated to improve product performance.
Provides an efficient target for antiviral agents.
Ready to use RNase-free solution with low toxicity to use with live cells for determination of RNA structure
Used for the optimization of transfection and verification of editing efficiency in transfected cells.
Ready-to-use, synthetic gRNAs maximizes and simplifies the performance of genome editing experiments.
Used for the optimization of transfection and verification of editing efficiency in transfected cells.
The EnGen sgRNA Synthesis Kit, S. pyogenes provides a simple and quick method for transcribing high yields of sgRNA in a single 30-minute reaction, using the supplied reagents and target-specific DNA oligos designed by the user.
The 5' terminal m7G cap present on most eukaryotic mRNAs promotes translation in vitro at the initiation level. For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs for protein synthesis. Certain prokaryotic mRNAs containing a 5' terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Also a cap requirement has been observed for splicing eukaryotic substrate RNAs. A method using E. coli RNA Polymerase primed with m7G(5' )ppp(5' )G or m7G(5' )ppp(5' )A for an efficient in vitro synthesis of capped RNAs has been developed by Contreas. Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m7G(5' )ppp(5' )G).
The 5' terminal m7G cap present on most eukaryotic mRNAs promotes translation in vitro at the initiation level. For most RNAs, elimination of the cap structure causes a loss of stability, especially against exonuclease degradation, and a decrease in the formation of the initiation complex of mRNAs for protein synthesis. Certain prokaryotic mRNAs containing a 5' terminal cap structure are translated as efficiently as or more efficiently than eukaryotic mRNAs in a eukaryotic cell-free protein synthesizing system. Also a cap requirement has been observed for splicing eukaryotic substrate RNAs. A method using E. coli RNA Polymerase primed with m7G(5' )ppp(5' )G or m7G(5' )ppp(5' )A for an efficient in vitro synthesis of capped RNAs has been developed by Contreas. Larger amounts of capped RNAs are produced by transcription systems using SP6 RNA polymerase primed with m7G(5' )ppp(5' )G.
CF550R MALEIMIDE 1 UMOL
CF570 MALEIMIDE 1 UMOL
CF583 MALEIMIDE 1 UMOL